免疫检查点抑制剂抑制实体瘤合并丙型肝炎病毒感染患者的丙型肝炎病毒复制
这项前瞻性观察研究纳入52例接受免疫检查点抑制剂(ICI)治疗的实体瘤合并慢性丙型肝炎病毒(HCV)感染患者,发现4例(7.7%)出现HCV抑制,其中1例未用直接抗病毒药物(DAA)即出现病毒血症检测不到持续6个月;2例(4%)出现HCV再激活,均发生于因ICI相关毒性接受免疫抑制治疗时;ICI相关不良事件以1-2级为主,未发生HCV相关肝衰竭或死亡。
要点
- ICI治疗期间4例(7.7%)出现HCV抑制,其中1例未用DAA即病毒血症检测不到持续6个月。
- 2例(4%)出现HCV再激活,均发生于因ICI相关毒性接受免疫抑制治疗时。
- 慢性HCV感染不应被视为ICI治疗的禁忌证。
核心结论
- 接受ICI治疗的患者中可出现HCV复制抑制甚至病毒学治愈,且无需DAA。
- HCV再激活主要发生于因ICI相关毒性接受免疫抑制治疗的患者。
- ICI在合并HCV感染的实体瘤患者中是安全的,慢性HCV感染不应被视为ICI治疗的禁忌证。
研究设计与样本
- 前瞻性观察研究,纳入2016年4月26日至2022年1月5日在本机构接受ICI治疗的实体瘤合并HCV感染患者。
- 共纳入52例连续患者。
- 主要结局为ICI引起的HCV病毒血症变化(HCV抑制和HCV再激活)及ICI安全性。
主要发现
- 4例患者(7.7%)在接受ICI期间出现HCV抑制,其中1例未用DAA即病毒血症检测不到持续6个月。
- 2例患者(4%)出现HCV再激活,均发生于因ICI相关毒性接受免疫抑制治疗时。
- 36例患者(69%)发生不良事件,47起不良事件中39起(83%)为1-2级。
- 8例患者(15%)发生3-4级不良事件,所有病例均与ICI相关,而非与HCV相关。
- 未发生HCV相关肝衰竭或死亡。
临床怎么用
- 原文结论指出慢性HCV感染不应被视为ICI治疗的禁忌证。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Data are scarce regarding the virologic impact and safety of immune checkpoint inhibitors (ICI) in patients with chronic hepatitis C virus (HCV) infection. We examined the virologic impact of ICI in HCV-infected patients with solid tumors and their safety. METHODS: HCV-infected patients with solid tumor treated with ICI at our institution between April 26, 2016, and January 5, 2022, were enrolled in a prospective observational study. The primary outcomes were ICI-induced changes in HCV viremia (HCV inhibition and HCV reactivation) and safety of ICI. RESULTS: We enrolled 52 consecutive patients with solid tumors treated with ICI. Most were men (41; 79%), White (31; 59%), without cirrhosis (34; 65%), and with HCV genotype 1 (40; 77%). Four patients (7.7%) experienced HCV inhibition while receiving ICI including 1 patient who developed undetectable viremia for 6 months in the absence of direct-acting antivirals (DAA). Two patients (4%) developed HCV reactivation, both while receiving immunosuppressive therapy for ICI-related toxic effects. Adverse events occurred in 36 patients (69%), and 39 of the 47 adverse events (83%) were grade 1-2. Grade 3-4 adverse events occurred in 8 patients (15%), and in all cases, they were related to ICI, not to HCV. No HCV-associated liver failure or death occurred. DISCUSSION: Inhibition of HCV replication with virologic cure can develop in patients receiving ICI without DAA. HCV reactivation occurs primarily in patients receiving immunosuppressants for ICI-related toxic effects. ICI are safe in HCV-infected patients with solid tumors. Chronic HCV infection should not be considered a contraindication for ICI therapy.
引用
- Yibirin M, Mustafayev K, Hosry J, et al. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. Am J Gastroenterol. 2023. PMID: 37307533. doi:10.14309/ajg.0000000000002361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。